It was another brutal year for cannabis stock investors in 2021 as the U.S. made very little regulatory progress on cannabis reform measures. Fortunately for cannabis stock investors, former hedge fund manager Whitney Tilson says he has high hopes for cannabis stocks in 2022.
Tilson’s Take: Last week, Tilson named the AdvisorShares Pure US Cannabis ETF (NYSE:MSOS) his “favorite pick for 2022” for investors.
Related Link: Cannabis Execs Talk ‘Silly’ Canadian Regulations, US, Expansion, The Value Of Good Partners
Tilson said he shares the bullish cannabis sentiment of Seabreeze Partners Management president Doug Kass.
Kass’ Case: In December, Kass said cannabis market fundamentals were strong and U.S. legislation would likely progress significantly in 2022.
“I see 2022 as a year of legislative breakthroughs, NYSE up-listings, M&A activity, and pent-up institutional demand for cannabis stocks,” Kass said.
Cannabis stocks were affected when the SAFE Act was not included in the National Defense Authorization Act legislation, however, Kass said the SAFE Act can simply be enacted faster than the market thinks, and can restore the qualifications of U. S. multistate operators. USA By 50 percent.
“The increasing likelihood of INCLUSION in ETFs, increasing NYSE’s board of directors, M&A activity and the pent-up ordering of hashish stocks, as custodian issues are resolved, can blend together to generate significant value gains in the short and medium term. “Kass said.
Benzinga’s point of view: Investors are indeed disappointed with the lack of U. S. progress in hashish reform efforts, especially with the Democrats who are the Houses of Congress and the White House.
The window for making significant legislative adjustments may close quickly, given that the PredictIt market suggests that Republicans lately have a 69% chance of taking either chamber of Congress in November.
See also: Which countries are most likely to legalize hashish in 2022 and why is the United States one of them?